Sarah Bos

25 Hemostatic profiles are similar across all etiologies of cirrhosis. 2 Baseline characteristics are reported in Table 1. In patients, the mean age across all etiologies was similar. BMI was highest in NASH patients, with a median [IQR] of 32.8 [28.3-36.8] kg/m2, and NASH patients had a substantially increased rate of diabetes compared to other etiologies. Model for end-stage liver disease (MELD) score was comparable across all etiologies. The majority of patients in the entire cohort (76%) had Childs Turcotte Pugh (CTP) A, with one single CTP C patient with ALD. PSC/PBC (n =31) NASH (n = 23) ALD (n = 37) Viral (n = 18) Control (n = 44) Age 59 (51-65) c 60 (54-64) c 60 (55-65) c 61 (53-65) c 30 (27-42) Male 13 (42 ) 12 (52 ) 26 (70 ) 16 (89) 38 (51) BMI (kg/m2) 24.7 (22.1-28.1) 32.8 (28.3-36.8) c 28.0 (23.8-31.1) b 28.1 (25.6-30.1) c 23.7 (22.3-25.5) Diabetes 5 (16) 18 (78) 9 (24) 3 (17) - CVD 4 (13) 10 (44) 13 (35) 2 (11) - MELD 9 (7-12] 8 (7-12] 10 (7-13] 8 (7-9] - CTP A 20 (65) 18 (78) 27 (73) 18 (100) - B 11 (35) 5 22) 9 (24) - - C - - 1 (3) - - Ascites, n (%) 6 (19) 8 (35) 10 (27) 2 (11) - Encephalopathy 0 4 (17) 5 (14) 0 - Platelet count (G/L) 122 (82-164) 114 (88-164) 111 (83-160) 130 (74-159) - Table 1. Patient characteristics Abbreviations: ALD, alcoholic liver disease, viral comprises hepatitis B and hepatitis C; BMI, body mass index; CTP, Child–Turcotte–Pugh; CVD, cardiovascular disease; MELD, Model for End-Stage Liver Disease; NASH, non-alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis. Note: Data are expressed as number (%), mean (standard deviation) or median (interquartile range). a p < 0.05 vs. control, b p < 0.01 vs. control, c p < 0.001 vs. control. Plasma levels of proteins involved in primary hemostasis VWF levels were significantly higher across all etiologies compared to controls (Figure 1). The highest VWF level was observed in ALD with a median of 347% [237- 492]. Despite elevated VWF levels, which have been proposed to support platelet deposition, we found lower levels of the platelet activation marker sP-selectin in patients compared to controls. ADAMTS13, which decreases the reactivity of VWF towards platelets by reducing VWF multimer size, was decreased in patients with cholestatic disease, but significantly increased in NASH. (Figure 1).